Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
ACP-105
ACP-105 is a partial agonist SARM developed by Acadia Pharmaceuticals. It was designed to provide anabolic benefits with reduced androgenic side effects. Very limited research data is available.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 899821-23-9 |
| Molecular Formula | C16H19ClN2O |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
ACP-105 acts as a partial agonist at androgen receptors. In animal studies it demonstrated anabolic effects on muscle and bone similar to testosterone propionate but with less effect on prostate weight. Its partial agonist nature may reduce side effects compared to full agonists.
Dosing Research
Only animal data exists. Research community references 5-10 mg/day based on extrapolation from animal studies. Half-life estimated at 6 hours. No established cycle protocols.
Side Effects & Risks
Virtually unknown in humans. Theoretical risks include mild hormonal suppression and potential liver stress. Considered lower risk than full agonist SARMs but with much less research to confirm this.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.